T. Rowe Price Investment Management
RCUS icon

T. Rowe Price Investment Management’s Arcus Biosciences RCUS Stock Holding History

T. Rowe Price Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,625
Closed -$39K – 870
2025
Q4 		$39K Buy
+1,625
New +$33.2K ﹤0.01% 675

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

T. Rowe Price Investment Management's RCUS Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Arcus Biosciences (RCUS) in Q1 2026, closing a stake of 1,625 shares — an estimated $39K sold.

T. Rowe Price Investment Management first reported a position in RCUS in Q4 2025 and held it in 1 quarter. The position peaked at $39K in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Arcus Biosciences position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,625 Arcus Biosciences shares in Q1 2026, an estimated $39K.
  • T. Rowe Price Investment Management first reported a position in Arcus Biosciences in Q4 2025 and held it in 1 quarter.
  • T. Rowe Price Investment Management's Arcus Biosciences position peaked at $39K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.